Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.

ABSTRACT:

Background

Brain metastases (BMs) are a key challenge in the management of anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC), but prognostic scores are complicated or rely on data before the era of tyrosine kinase inhibitors (TKIs). This study aimed to validate the novel ALK-Brain Prognostic Index (ALK-BPI), which was originally proposed based on 44 TKI-treated ALK+ NSCLC patients from Karolinska University Hospital, using an external clinical cohort.

Patients and methods

TKI-treated ALK+ NSCLC patients with BM from Heidelberg (n = 82, cohort 1) were retrospectively analyzed alone and together with the original Karolinska cohort (n = 126, cohort 2). Cox regression models were used to determine the association of clinical variables and scores with

SUBMITTER: Zerdes I 

PROVIDER: S-EPMC10774967 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature